| Name | Title | Contact Details |
|---|
Visit the orthopedic surgeons and spine specialists at Envision Ortho, serving patients in Atlanta, Augusta, and Savannah, Georgia.
Eupraxia is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to currently approved drugs. Each of Eupraxia`s product candidates has the potential to address therapeutic areas with high unmet medical need, and strives to provide improved patient benefit by delivering targeted, long-lasting activity with fewer side effects. In addition to Eupraxia`s lead product candidate, EP-104IAR, Eupraxia is developing a pipeline of earlier-stage long-acting formulations. Potential pipeline candidates include a range of drugs for indications such as post-surgical pain (EP-105), and post-surgical site infections (EP-201), each designed to improve on the activity and tolerability of approved drugs. Eupraxia is also developing a formulation of EP-104IAR for use in canine and equine osteoarthritis.
Advancing RF Technology for the treatment of chronic pain. Nimbus provides a large volume lesion that is cost effective and easy to use.
Stone & Magnanini is a New York, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.